View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
October 18, 2019updated 02 Dec 2021 5:26am

FDA approves Secuado patch for Schizophrenia

Secuado is the first and only transdermal patch formulation to be approved for treating schizophrenia.

By GlobalData Healthcare

Noven Pharmaceuticals (a subsidiary of Hisamitsu Pharmaceutical) has announced that its Secuado (asenapine) has been approved by the US Food and Drug Administration (FDA) and will be available on the US market for adult schizophrenia patients. 

Secuado is the first and only transdermal patch formulation to be approved for treating schizophrenia. Unlike treatments currently available on the market, Secuado’s patch formulation makes it easier for caregivers and healthcare providers to administer. 

The patch has the potential to be commercially successful because it will significantly simplify managing symptoms in a non-invasive formulation. 

Secuado is administered once per day via a transdermal drug delivery system that provides sustained concentrations of antipsychotic asenapine during the recommended wear time of 24 hours. Clinical studies evaluating the safety and efficacy of Secuado found that the product led to statistically significant improvement based on the Clinical Global Impression-Severity scale. However, clinical studies have also shown adverse effects such as extrapyramidal disorder, application site reactions, and weight gain. 

The schizophrenia market is known for its high levels of clinical need. Secuado offers an alternative to the use of intrusive treatments to manage symptoms and gives a visual confirmation that the treatment is being used. Although Secuado has received FDA approval, it will need to be evaluated by caregivers and healthcare providers before its gains widespread use, so the treatment may still face a slow uptake in the schizophrenia market.  


Related Report:

Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2019

Related Companies

Related Report
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy